AFM24

About Affimed

Affimed is a Germany-based immuno-oncology company dedicated to developing first-in-class innate cell engagers (ICE®) for cancer. Its core achievement is the proprietary ROCK® platform, which generates tetravalent, bispecific antibodies engineered to potently activate NK cells and macrophages against tumors. The company's strategy centers on advancing its lead candidate, AFM13, in combination with allogeneic NK cells for relapsed/refractory Hodgkin lymphoma, while leveraging its platform to build a broader pipeline. Affimed operates as a public company, collaborating with key partners to validate and expand the potential of its innate immunity approach.

Therapeutic Areas

Other EGFR-positive Solid Tumors Drugs